tiprankstipranks
Advertisement
Advertisement

ARWR Stock Latest News

Arrowhead price target raised to $120 from $100 at Morgan Stanley
The FlyArrowhead price target raised to $120 from $100 at Morgan Stanley
17h ago
ARWR
Arrowhead price target raised to $126 from $110 at Piper Sandler
PremiumThe Fly
Arrowhead price target raised to $126 from $110 at Piper Sandler
19h ago
ARWR
Arrowhead price target raised to $115 from $90 at Chardan
PremiumThe Fly
Arrowhead price target raised to $115 from $90 at Chardan
2d ago
ARWR
Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results
PremiumMarket News
Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results
2d ago
ARWR
Arrowhead’s ARO-033 First-in-Human Trial: What Early Safety Progress Means for ARWR Investors
PremiumCompany Announcements
Arrowhead’s ARO-033 First-in-Human Trial: What Early Safety Progress Means for ARWR Investors
2d ago
ARWR
Midday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
PremiumThe FlyMidday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
2d ago
T
PM
Arrowhead rises 23.4%
Premium
The Fly
Arrowhead rises 23.4%
2d ago
ARWR
Arrowhead rises 22.7%
Premium
The Fly
Arrowhead rises 22.7%
2d ago
ARWR
Arrowhead announces Phase 3 SHASTA-3, SHASTA-4 met primary endpoint
PremiumThe Fly
Arrowhead announces Phase 3 SHASTA-3, SHASTA-4 met primary endpoint
2d ago
ARWR
Arrowhead price target raised to $95 from $88 at JPMorgan
PremiumThe Fly
Arrowhead price target raised to $95 from $88 at JPMorgan
7d ago
ARWR
Arrowhead initiated with a Buy at Stifel
PremiumThe Fly
Arrowhead initiated with a Buy at Stifel
10d ago
ARWR
IONS
Buy Rating Reiterated on Arrowhead as Cardiometabolic RNAi Portfolio Advances; $100 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on Arrowhead as Cardiometabolic RNAi Portfolio Advances; $100 Price Target Maintained
23d ago
ARWR
Arrowhead receives MAA in the EU for REDEMPLO
PremiumThe FlyArrowhead receives MAA in the EU for REDEMPLO
1M ago
ARWR
Arrowhead Pharmaceuticals Adds Experienced Healthcare Investor to Board
Premium
Company Announcements
Arrowhead Pharmaceuticals Adds Experienced Healthcare Investor to Board
1M ago
8K
ARWR
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
Premium
TipRanks Newswire
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
2M ago
NVO
ARWR
Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play
PremiumCompany Announcements
Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play
2M ago
ARWR
Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained
PremiumRatings
Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained
2M ago
ARWR
Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE
PremiumThe Fly
Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE
2M ago
ARWR
Arrowhead presents clinical cardiometabolic data at EAS Congress
PremiumThe Fly
Arrowhead presents clinical cardiometabolic data at EAS Congress
2M ago
ARWR
Arrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors
PremiumCompany AnnouncementsArrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors
2M ago
ARWR
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next
Premium
Company Announcements
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next
2M ago
ARWR
Arrowhead price target raised to $46 from $35 at Bernstein
Premium
The Fly
Arrowhead price target raised to $46 from $35 at Bernstein
2M ago
ARWR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >